Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
Gillham C, Zips D, Pönisch F, Evers C, Enghardt W, Abolmaali N, Zöphel K, Appold S, Hölscher T, Steinbach J, Kotzerke J, Herrmann T, Baumann M. Gillham C, et al. Among authors: appold s. Radiother Oncol. 2008 Sep;88(3):335-41. doi: 10.1016/j.radonc.2008.05.004. Epub 2008 May 29. Radiother Oncol. 2008. PMID: 18514339
Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer.
Hentschel M, Appold S, Schreiber A, Abolmaali N, Abramyuk A, Dörr W, Kotzerke J, Baumann M, Zöphel K. Hentschel M, et al. Among authors: appold s. Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1203-11. doi: 10.1007/s00259-011-1759-3. Epub 2011 Feb 25. Eur J Nucl Med Mol Imaging. 2011. PMID: 21350962 Clinical Trial.
GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: subgroup analysis of the prospective randomized CHARTWEL trial.
Soliman M, Yaromina A, Appold S, Zips D, Reiffenstuhl C, Schreiber A, Thames HD, Krause M, Baumann M. Soliman M, et al. Among authors: appold s. Radiother Oncol. 2013 Mar;106(3):299-304. doi: 10.1016/j.radonc.2012.12.008. Epub 2013 Jan 17. Radiother Oncol. 2013. PMID: 23333018 Clinical Trial.
Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure.
Zschaeck S, Haase R, Abolmaali N, Perrin R, Stützer K, Appold S, Steinbach J, Kotzerke J, Zips D, Richter C, Gudziol V, Krause M, Zöphel K, Baumann M. Zschaeck S, et al. Among authors: appold s. Acta Oncol. 2015;54(9):1355-63. doi: 10.3109/0284186X.2015.1074720. Epub 2015 Sep 23. Acta Oncol. 2015. PMID: 26398663 Clinical Trial.
FDG uptake in normal tissues assessed by PET during treatment has prognostic value for treatment results in head and neck squamous cell carcinomas undergoing radiochemotherapy.
Zschaeck S, Löck S, Leger S, Haase R, Bandurska-Luque A, Appold S, Kotzerke J, Zips D, Richter C, Gudziol V, Schreiber A, Zöphel K, Baumann M, Krause M. Zschaeck S, et al. Among authors: appold s. Radiother Oncol. 2017 Mar;122(3):437-444. doi: 10.1016/j.radonc.2017.01.019. Epub 2017 Feb 17. Radiother Oncol. 2017. PMID: 28222892
56 results